Lifecore Biomedical, Inc. (LFCR)
USD 7.29
(6.73%)
USD 7.29
(6.73%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | 12.01 Million USD | 111.76% |
| 2023 | -102.19 Million USD | -121.75% |
| 2022 | -46.08 Million USD | -41.08% |
| 2021 | -32.66 Million USD | 14.47% |
| 2020 | -38.19 Million USD | -1899.76% |
| 2019 | 2.12 Million USD | -91.45% |
| 2018 | 24.82 Million USD | 134.46% |
| 2017 | 10.59 Million USD | 190.97% |
| 2016 | -11.64 Million USD | -185.95% |
| 2015 | 13.54 Million USD | -29.26% |
| 2014 | 19.14 Million USD | -15.24% |
| 2013 | 22.58 Million USD | 77.91% |
| 2012 | 12.69 Million USD | 223.88% |
| 2011 | 3.92 Million USD | -1.61% |
| 2010 | 3.98 Million USD | -48.46% |
| 2009 | 7.73 Million USD | -42.92% |
| 2008 | 13.54 Million USD | -53.61% |
| 2007 | 29.18 Million USD | 237.41% |
| 2006 | 8.65 Million USD | 60.14% |
| 2005 | 5.4 Million USD | 86.28% |
| 2004 | 2.9 Million USD | 0.0% |
| 2003 | - USD | 100.0% |
| 2002 | -1.48 Million USD | 92.08% |
| 2001 | -18.78 Million USD | -369.91% |
| 2000 | -3.99 Million USD | -42.79% |
| 1999 | -2.8 Million USD | 3.45% |
| 1998 | -2.9 Million USD | 66.28% |
| 1997 | -8.6 Million USD | -104.76% |
| 1996 | -4.2 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 14.21 Million USD | 232.21% |
| 2024 Q1 | -10.75 Million USD | 70.24% |
| 2024 Q3 | 15.63 Million USD | 9.95% |
| 2024 FY | 12.01 Million USD | 111.76% |
| 2024 Q4 | -7.08 Million USD | -145.31% |
| 2023 Q1 | -11.35 Million USD | 68.88% |
| 2023 Q2 | -12.44 Million USD | -9.67% |
| 2023 Q4 | -36.13 Million USD | -133.68% |
| 2023 FY | -102.19 Million USD | -121.75% |
| 2023 Q3 | -15.46 Million USD | -24.19% |
| 2022 Q3 | -12.85 Million USD | 66.57% |
| 2022 Q1 | -9.47 Million USD | -230.44% |
| 2022 Q2 | -38.44 Million USD | -305.62% |
| 2022 Q4 | -36.47 Million USD | -183.82% |
| 2022 FY | -46.08 Million USD | -41.08% |
| 2021 Q4 | -2.86 Million USD | 47.84% |
| 2021 FY | -32.66 Million USD | 14.47% |
| 2021 Q3 | -5.49 Million USD | 58.66% |
| 2021 Q1 | -11 Million USD | 27.39% |
| 2021 Q2 | -13.3 Million USD | -20.92% |
| 2020 Q1 | -4.78 Million USD | -1725.95% |
| 2020 FY | -38.19 Million USD | -1899.76% |
| 2020 Q2 | -6.74 Million USD | -40.89% |
| 2020 Q3 | -11.51 Million USD | -70.89% |
| 2020 Q4 | -15.14 Million USD | -31.52% |
| 2019 Q3 | 1.06 Million USD | 282.71% |
| 2019 FY | 2.12 Million USD | -91.45% |
| 2019 Q4 | -262 Thousand USD | -124.55% |
| 2019 Q1 | 190 Thousand USD | -96.89% |
| 2019 Q2 | -584 Thousand USD | -407.37% |
| 2018 Q4 | 6.1 Million USD | -62.03% |
| 2018 Q3 | 16.08 Million USD | 3203.49% |
| 2018 Q2 | 487 Thousand USD | -77.31% |
| 2018 Q1 | 2.14 Million USD | -12.48% |
| 2018 FY | 24.82 Million USD | 134.46% |
| 2017 Q1 | 3.31 Million USD | -29.96% |
| 2017 FY | 10.59 Million USD | 190.97% |
| 2017 Q4 | 2.45 Million USD | -29.94% |
| 2017 Q3 | 3.5 Million USD | 163.95% |
| 2017 Q2 | 1.32 Million USD | -59.96% |
| 2016 FY | -11.64 Million USD | -185.95% |
| 2016 Q3 | -21.19 Million USD | -1234.37% |
| 2016 Q4 | 4.72 Million USD | 122.32% |
| 2016 Q1 | 2.95 Million USD | -29.65% |
| 2016 Q2 | 1.86 Million USD | -36.72% |
| 2015 Q3 | 3.77 Million USD | 17.03% |
| 2015 Q4 | 4.19 Million USD | 11.24% |
| 2015 FY | 13.54 Million USD | -29.26% |
| 2015 Q2 | 3.22 Million USD | 36.97% |
| 2015 Q1 | 2.35 Million USD | -48.19% |
| 2014 Q4 | 4.54 Million USD | -29.03% |
| 2014 Q2 | 3.45 Million USD | -27.38% |
| 2014 Q1 | 4.75 Million USD | 5.16% |
| 2014 FY | 19.14 Million USD | -15.24% |
| 2014 Q3 | 6.4 Million USD | 85.45% |
| 2013 Q3 | 4.78 Million USD | -46.27% |
| 2013 Q1 | 2.53 Million USD | -8.64% |
| 2013 Q4 | 4.51 Million USD | -5.64% |
| 2013 Q2 | 8.91 Million USD | 251.04% |
| 2013 FY | 22.58 Million USD | 77.91% |
| 2012 Q2 | 3.34 Million USD | 84.33% |
| 2012 Q4 | 2.77 Million USD | -41.68% |
| 2012 FY | 12.69 Million USD | 223.88% |
| 2012 Q1 | 1.81 Million USD | 166.2% |
| 2012 Q3 | 4.76 Million USD | 42.66% |
| 2011 FY | 3.92 Million USD | -1.61% |
| 2011 Q2 | 2.05 Million USD | -10.81% |
| 2011 Q3 | 2.29 Million USD | 11.82% |
| 2011 Q4 | -2.73 Million USD | -219.1% |
| 2011 Q1 | 2.3 Million USD | 256.95% |
| 2010 FY | 3.98 Million USD | -48.46% |
| 2010 Q3 | 1.73 Million USD | 13.04% |
| 2010 Q1 | 2.18 Million USD | -3.32% |
| 2010 Q2 | 1.53 Million USD | -29.76% |
| 2010 Q4 | -1.46 Million USD | -184.66% |
| 2009 Q2 | 1.49 Million USD | -47.23% |
| 2009 FY | 7.73 Million USD | -42.92% |
| 2009 Q4 | 2.25 Million USD | 46.69% |
| 2009 Q1 | 2.83 Million USD | -15.86% |
| 2009 Q3 | 1.54 Million USD | 2.8% |
| 2008 Q2 | 3.12 Million USD | 1.56% |
| 2008 FY | 13.54 Million USD | -53.61% |
| 2008 Q4 | 3.37 Million USD | -12.25% |
| 2008 Q3 | 3.84 Million USD | 23.04% |
| 2008 Q1 | 3.07 Million USD | -30.4% |
| 2007 FY | 29.18 Million USD | 237.41% |
| 2007 Q4 | 4.42 Million USD | -82.06% |
| 2007 Q3 | 24.64 Million USD | 22719.44% |
| 2007 Q2 | 108 Thousand USD | 671.43% |
| 2007 Q1 | 14 Thousand USD | -99.79% |
| 2006 Q1 | -521 Thousand USD | -111.3% |
| 2006 FY | 8.65 Million USD | 60.14% |
| 2006 Q2 | -1.03 Million USD | -99.04% |
| 2006 Q3 | 3.51 Million USD | 438.86% |
| 2006 Q4 | 6.69 Million USD | 90.5% |
| 2005 Q3 | 2.29 Million USD | 383.79% |
| 2005 FY | 5.4 Million USD | 86.28% |
| 2005 Q4 | 4.6 Million USD | 101.0% |
| 2005 Q2 | -808 Thousand USD | -16.76% |
| 2005 Q1 | -692 Thousand USD | -116.23% |
| 2004 Q1 | -624 Thousand USD | -113.68% |
| 2004 Q3 | 608 Thousand USD | 138.41% |
| 2004 Q4 | 4.26 Million USD | 601.15% |
| 2004 FY | 2.9 Million USD | 0.0% |
| 2004 Q2 | -1.58 Million USD | -153.69% |
| 2003 Q2 | -2.9 Million USD | -503.53% |
| 2003 Q3 | -2.03 Million USD | 30.01% |
| 2003 FY | - USD | 100.0% |
| 2003 Q4 | 4.56 Million USD | 324.12% |
| 2003 Q1 | -482 Thousand USD | -109.06% |
| 2002 Q4 | 5.32 Million USD | 251.18% |
| 2002 Q1 | -1.34 Million USD | -142.27% |
| 2002 Q2 | -16.68 Million USD | -1140.52% |
| 2002 Q3 | -3.52 Million USD | 78.9% |
| 2002 FY | -1.48 Million USD | 92.08% |
| 2001 Q4 | 3.18 Million USD | 180.78% |
| 2001 Q3 | -3.93 Million USD | -15.28% |
| 2001 Q2 | -3.41 Million USD | -416.16% |
| 2001 Q1 | -662 Thousand USD | -122.76% |
| 2001 FY | -18.78 Million USD | -369.91% |
| 2000 FY | -3.99 Million USD | -42.79% |
| 2000 Q2 | -2.6 Million USD | -30.0% |
| 2000 Q4 | 2.9 Million USD | 207.7% |
| 2000 Q3 | -2.7 Million USD | -3.85% |
| 2000 Q1 | -2 Million USD | -157.14% |
| 1999 Q1 | -1.3 Million USD | -150.0% |
| 1999 Q2 | -2.6 Million USD | -100.0% |
| 1999 Q3 | -1.6 Million USD | 38.46% |
| 1999 Q4 | 3.5 Million USD | 318.75% |
| 1999 FY | -2.8 Million USD | 3.45% |
| 1998 Q2 | -1.7 Million USD | -70.0% |
| 1998 Q3 | -1.6 Million USD | 5.88% |
| 1998 Q4 | 2.6 Million USD | 262.5% |
| 1998 FY | -2.9 Million USD | 66.28% |
| 1998 Q1 | -1 Million USD | 78.26% |
| 1997 FY | -8.6 Million USD | -104.76% |
| 1997 Q2 | -1.7 Million USD | -70.0% |
| 1997 Q3 | -1.3 Million USD | 23.53% |
| 1997 Q4 | -4.6 Million USD | -253.85% |
| 1997 Q1 | -1 Million USD | -233.33% |
| 1996 Q3 | -1.2 Million USD | 0.0% |
| 1996 FY | -4.2 Million USD | 0.0% |
| 1996 Q4 | -300 Thousand USD | 75.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 36.03% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 252.643% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 75.053% |
| Cosmos Health Inc. | -18.54 Million USD | 164.786% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 159.893% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 105.741% |
| Cronos Group Inc. | -73.96 Million USD | 116.242% |
| Incannex Healthcare Limited | -18.45 Million USD | 165.079% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 128.467% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 379.253% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 366.597% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 366.597% |
| SCYNEXIS, Inc. | 67.04 Million USD | 82.081% |
| Safety Shot Inc | -15.08 Million USD | 179.646% |
| Theratechnologies Inc. | -23.95 Million USD | 150.144% |
| Alpha Teknova, Inc. | -36.78 Million USD | 132.662% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 294.919% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 71.367% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 348.459% |
| Dynavax Technologies Corporation | -6.38 Million USD | 288.026% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 101.199% |
| Radius Health, Inc. | -25.79 Million USD | 146.578% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | 487.7% |
| Alvotech | -551.73 Million USD | 102.177% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 108.601% |
| SIGA Technologies, Inc. | 68.06 Million USD | 82.352% |
| Shineco, Inc. | -22.44 Million USD | 153.512% |
| Silver Spike Investment Corp. | 7.34 Million USD | -63.662% |
| Journey Medical Corporation | -3.85 Million USD | 411.783% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 247.161% |
| Embecta Corp. | 70.4 Million USD | 82.936% |
| Harrow Health, Inc. | -24.41 Million USD | 149.211% |
| Procaps Group, S.A. | 42.54 Million USD | 71.761% |
| Biofrontera Inc. | -20.13 Million USD | 159.674% |
| DURECT Corporation | -27.62 Million USD | 143.488% |
| PainReform Ltd. | -9.34 Million USD | 228.564% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -812.842% |
| OptiNose, Inc. | -35.48 Million USD | 133.856% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 49.77% |
| Organogenesis Holdings Inc. | 4.94 Million USD | -142.932% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 291.311% |
| ProPhase Labs, Inc. | -16.78 Million USD | 171.583% |
| Phibro Animal Health Corporation | 2.41 Million USD | -397.227% |
| Procaps Group S.A. | 42.54 Million USD | 71.761% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 216.881% |
| Viatris Inc. | 54.7 Million USD | 78.038% |
| Rockwell Medical, Inc. | -8.43 Million USD | 242.351% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 175.82% |
| Tilray Brands, Inc. | -244.98 Million USD | 104.904% |
| PetIQ, Inc. | 2.13 Million USD | -463.726% |
| Talphera, Inc. | -18.39 Million USD | 165.299% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 95.189% |
| Alimera Sciences, Inc. | -20.13 Million USD | 159.671% |
| Assertio Holdings, Inc. | -331.94 Million USD | 103.619% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 282.216% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 107.495% |
| Hempacco Co., Inc. | -13.12 Million USD | 191.52% |
| Alvotech | -551.73 Million USD | 102.177% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 96.322% |
| Kamada Ltd. | 8.28 Million USD | -45.014% |
| Currenc Group, Inc. | -15.3 Million USD | 178.483% |
| Indivior PLC | 2 Million USD | -500.65% |
| Evoke Pharma, Inc. | -7.79 Million USD | 254.165% |
| Flora Growth Corp. | -57.03 Million USD | 121.062% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 159.893% |
| Evolus, Inc. | -61.68 Million USD | 119.475% |
| HUTCHMED (China) Limited | 100.78 Million USD | 88.08% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 91.266% |
| Akanda Corp. | -32.27 Million USD | 137.221% |